Chong Kun Dang targets Japanese market with domestically-first Nesp biosimilar

Chong Kun Dang(CEO Young-joo Kim) will target the Japanese market with ‘CKD-11101,’ a biosimilar of Nesp, the 2^nd generation anemia treatment, which has been being developed for the first time in the domestic industry.

On the 5^th, Chong Kun Dang announced establishment of the agreement to export the CKD-11101 technology with Japanese Fuji Pharma.

Under the term of the agreement, Fuji Pharma w...